Show simple item record

dc.contributor.authorOrchard, Jen_US
dc.contributor.authorGarand, Ren_US
dc.contributor.authorDavis, Zen_US
dc.contributor.authorBabbage, Gen_US
dc.contributor.authorSahota, Sen_US
dc.contributor.authorMatutes, Een_US
dc.contributor.authorCatovsky, Den_US
dc.contributor.authorThomas, PWen_US
dc.contributor.authorAvet-Loiseau, Hen_US
dc.contributor.authorOscier, Den_US
dc.date.accessioned2018-09-13T08:39:18Z
dc.date.issued2003-06-15en_US
dc.identifier12en_US
dc.identifier.citationBLOOD, 2003, 101 pp. 4975 - 4981en_US
dc.identifier.issn0006-4971en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2676
dc.identifier.doi10.1182/blood-2002-06-1864en_US
dc.description.abstractWe analyzed lymphocyte morphology, histology, immunophenotype, immunoglobulin heavy chain (IgV(H)) gene mutations, and clinical course in 80 unselected patients presenting with circulating t(11;14) lymphocytes. Of the 80 patients, 43 had peripheral lymphadenopathy (nodal group), and histology confirmed mantle cell lymphoma (MCL) in all. There were 37 patients with no lymphadenopathy (nonnodal group); 13 of 37 had histology, all showing MCL. IgV(H) genes were unmutated in 28 (90%) of 31 nodal and 15 (44%) of 34 nonnodal cases (P = .0001); CD38 was positive in 32 (94%) of 34 nodal and 16 (48%) of 33 nonmodal cases (P < .001); 41 (95%) of 43 nodal patients required immediate treatment compared with 18 (49%) of 37 nonnodal patients who had indolent disease (P < .0001). Median survival (95% confidence interval) was 30 months (10-50) in the nodal group and 79 months (22-136) in the nonnodal group (P = .005). Mutation status did not statistically affect survival, but of 6 long-term survivors (> 90 months) all were nonnodal and 5 of 5 had mutated IgV(H) genes. Lymphocyte morphology was heterogeneous in both groups: typical MCL in 56 cases (34 nodal, 22 nonmodal), blastoid MCL in 8 cases (3 nodal, 5 nonmodal), and small-cell MCL in 16 cases (6 nodal, 10 nonnodal, P = .12). Matutes immunophenotyping score was 1 in 65 cases and 2 in 15 (8 nodal, 7 nonnodal). We find no evidence against a diagnosis of MCL in the nonnodal group and suggest that mutated IgV(H) genes may help identify patients with indolent disease. (C) 2003 by The American Society of Hematology.en_US
dc.format.extent4975 - 4981en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherAMER SOC HEMATOLOGYen_US
dc.titleA subset of t(11;14) lymphoma with mantle cell features displays mutated IgV(H) genes and includes patients with good prognosis, nonnodal diseaseen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1182/blood-2002-06-1864en_US
rioxxterms.licenseref.startdate2003-06-15en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBLOODen_US
pubs.notesaffiliation: Oscier, D (Reprint Author), Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England. Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England. Univ Hosp, Haematol Lab, Nantes, France. Univ Hosp, Tenovus Res Lab, Southampton, Hants, England. Royal Marsden NHS Trust, Acad Dept Haematol & Cytogenet, London, England. Poole Hosp, Dorset Res & Dev Support Unit, Poole, Dorset, England. keywords-plus: CHRONIC LYMPHOCYTIC-LEUKEMIA; CHRONIC LYMPHOPROLIFERATIVE DISORDERS; POLYMERASE-CHAIN-REACTION; MARGINAL ZONE LYMPHOMA; SOMATIC MUTATIONS; CYCLIN D1; BCL-1 REARRANGEMENTS; BLASTOID VARIANTS; CD38 EXPRESSION; FOLLICLE MANTLE research-areas: Hematology web-of-science-categories: Hematology author-email: david.oscier@lineone.net orcid-numbers: Thomas, Peter/0000-0003-2478-4324 number-of-cited-references: 48 times-cited: 167 usage-count-last-180-days: 0 usage-count-since-2013: 7 journal-iso: Blood doc-delivery-number: 689FV unique-id: ISI:000183481700057 oa: gold_or_bronze da: 2018-09-12en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume101en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorCatovsky, Danielen_US
dc.contributor.icrauthorMatutes, Estellaen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record